Roth Capital Starts Rigel Pharmaceuticals (RIGL) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Leerink Swann Starts Rigel Pharmaceuticals (RIGL) at Outperform; Top Biotech with Two Drivers
September 6, 2012 7:05 AM EDTLeerink Swann initiates coverage on Rigel Pharmaceuticals (NASDAQ: RIGL) with an Outperform. PT $16.00.
Analyst, Irene Lau, said, "RIGL is a top biotech pick for us over the next 12 months based on potential for AZN-partnered Fostamatinib (Fos-D, syk-kinase inhibitor) and proprietary R343... More
